All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, February 27, 2021
Home » Blogs » BioWorld MedTech Perspectives » Ultrasound patch could aid in patient healing

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

Ultrasound patch could aid in patient healing

Aug. 9, 2013
By Omar Ford
No Comments

WolverineMarvel Comics' popular character Wolverine is known for his ability to heal from nearly any wound. Researchers at Drexel University in Philadelphia have developed an ultrasound technology aimed at giving patients who suffer from chronic wounds, an extra boost in recovering from the injuries.

And while it's not anywhere near the level of Wolverine's powers (he is a fictional character after all), initial studies show promising results for the device. In the study, researchers treated patients suffering from venous ulcers, which account for 80% of all chronic wounds found on lower extremities and affect approximately 500,000 U.S. patients annually, a number that’s expected to increase as obesity rates climb. It’s estimated that treatment for venous ulcers costs the U.S. healthcare system over $1 billion dollars per year.

Researchers applied the device to patients for 15 to 45 minutes, once a week, while they were seeing their physician for a routine appointment. The end results was improved healing compared to the control group that did not receive treatment.

I interviewed some of the researchers involved in this project, and while there are definite plans to try and get this technology into the market place, there is also a sense of urgency.

Joshua Samuels, one of the researchers in the study spoke passionately about the technology and perhaps gave one of the most heartfelt interviews that I have had in my six years here at Medical Device Daily. I think his quote pretty much sums up the pure unbridled mission of med-tech.

“It’s always slow moving getting it from the research lab to the market place,” Samuels said. “What I would really like to see is the device get used by patients as quick as possible. It’s always tough when you do biomedical research knowing that it could take six to seven years to get onto the market place. I know that there are regulations and I know that everything has to go through its due process, but that’s something I would really like to see – to get to patients so that it can help them.”

Here's hoping that happens.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Seniors with wooden puzzle

    Cassava’s simufilam improves AD patients’ cognition, behavior

    BioWorld
    When Cassava Sciences Inc.’s president and CEO, Remi Barbier, opened up the interim analysis of the company’s open-label study for Alzheimer’s disease candidate...
  • Vaxart COVID-19 vaccine tablets

    Vaxart shares shaken despite apparently positive early data for oral COVID-19 vaccine

    BioWorld
    Vaxart Inc. investors who stuck by company shares Feb. 3 had to swallow a bitter pill – watching shares of the oral vaccine developer (NASDAQ:VXRT) fall 57.8% to...
  • IPO money

    Lucira Health launches $153M IPO

    BioWorld MedTech
    Infectious diseases diagnostics company Lucira Health Inc. launched an IPO of 9 million shares of common stock at $17 per share, for expected gross proceeds of...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 26.
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing